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Background. The risk of individuals infected with human immunodeficiency virus (HIV)-1 developing tuberculosis (TB) is 
high, while both prognostic and diagnostic tools remain insensitive. The potential for plasma biomarkers to predict which HIV-1–
infected individuals are likely to progress to active disease is unknown.
Methods. Thirteen analytes were measured from QuantiFERON Gold in-tube (QFT) plasma samples in 421 HIV-1–infected 
persons recruited within the screening and enrollment phases of a randomized, controlled trial of isoniazid preventive therapy. 
Blood for QFT was obtained pre-randomization. Individuals were classified into prevalent TB, incident TB, and control groups. 
Comparisons between groups, supervised learning methods, and weighted correlation network analyses were applied utilizing the 
unstimulated and background-corrected plasma analyte concentrations.
Results. Unstimulated samples showed higher analyte concentrations in the prevalent and incident TB groups compared to the 
control group. The largest differences were seen for C-X-C motif chemokine 10 (CXCL10), interleukin-2 (IL-2), IL-1α, transforming 
growth factor-α (TGF-α). A predictive model analysis using unstimulated analytes discriminated best between the control and prev-
alent TB groups (area under the curve [AUC] = 0.9), reasonably well between the incident and prevalent TB groups (AUC > 0.8), and 
poorly between the control and incident TB groups. Unstimulated IL-2 and IFN-γ were ranked at or near the top for all comparisons, 
except the comparison between the control vs incident TB groups. Models using background-adjusted values performed poorly.
Conclusions. Single plasma biomarkers are unlikely to distinguish between disease states in HIV-1 co-infected individuals, and 
combinations of biomarkers are required. The ability to detect prevalent TB is potentially important, as no blood test hitherto has 
been suggested as having the utility to detect prevalent TB amongst HIV-1 co-infected persons.
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Tuberculosis (TB) associated with human immunodefi-
ciency virus (HIV)-1 is a health burden in Africa, despite 
implementation of the World Health Organization’s direct-
ly-observed, short-course therapy strategy for TB; the wide-
spread roll-out of combination antiretroviral therapy (ART); 
and guidelines to increase provision of isoniazid preventive 
therapy (IPT). The risk of developing TB in HIV-1–infected 
people exceeds that in HIV-1–uninfected people, even after 
accounting for risk reduction by ART [1–3]. HIV-1 co-in-
fection impacts TB-specific immune responses, causing 
false negative results in immune tests of TB sensitization. 
Currently, testing for latent TB infection (LTBI) is performed 
by either Tuberculin skin testing (TST) or interferon gamma 
release assays (IGRA). HIV-1 infection impairs the sensi-
tivity of both of these tests [4–6], underestimating those who 
would benefit from IPT, particularly amongst those newly 
commencing ART, leading to vulnerable patients potentially 
being untreated.
The role of IPT to decrease the risk of TB in HIV-1–infected 
people is well-recognized [7]. A randomized, controlled trial 
(RCT) of IPT plus ART versus ART alone for the prevention 
of TB in a large, well-characterized group of HIV-1–infected 
persons conducted in Khayelitsha, South Africa (ART-IPT 
Study), established that TST- or IGRA-negative, HIV-infected 
persons on ART also benefit from IPT [8]. Thus, current tests 
for latent TB imperfectly identify those likely to benefit from 
IPT. It is not known whether tests evaluating an extended 
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spectrum of biomarkers in plasma would enhance the risk 
stratification of infected individuals, as studies assessing bio-
markers other than interferon (IFN)-γ to predict active di-
sease or potential benefits from IPT are lacking. There is an 
urgent need for tests that can distinguish prevalent TB from 
LTBI, as the fear of treating TB with IPT monotherapy is a 
major barrier to IPT implementation.
Here, we investigated the predictive performance of 13 
preselected analytes determined from QuantiFERON Gold 
in-tube (QFT) plasma samples from HIV-1–infected persons 
screened for the ART-IPT Study. Patients were grouped into 
those with prevalent (active) TB that were screened out prior 
to RCT randomization; those who developed TB either after 
randomization or during the longitudinal follow-up (incident 
TB); and those who did not develop TB (controls). Analytes 
(Supplementary Table S1) were selected for their relevance in 
active TB and LTBI based on the available literature at the time 
of the study design, with the hypothesis that those biomarkers 
that are elevated at baseline in patients who either go on to have 
active TB (and thus should not start IPT) or go on to develop 
TB during longitudinal follow-up could be potential biomark-
ers predictive of TB.
METHODS
Study Design and Participants
This study was conducted within the screening and follow-up of 
a previously-reported, randomized, controlled trial [8]. Briefly, 
a pragmatic, individually-randomized, double-blind, place-
bo-controlled trial of IPT in adults with HIV-1 infection was 
conducted between 31 January 2008 and 31 September 2011. 
Patients were prescribed, or commencing, ART at the Ubuntu 
clinic in Khayelitsha, South Africa. Ethical approval was 
obtained from the University of Cape Town Faculty of Health 
Sciences Human Research Ethics Committee both for the trial 
(REC/REF: 013/2007) and for the laboratory sub-study (REC/
REF: 245/2009). Written consent or a thumb-print was required 
from all participants prior to screening. A total of 421 persons 
were included in this analysis, based on IGRA sample availa-
bility at screening, and included 51 individuals who developed 
clinically- or microbiologically-confirmed TB during the 4-year 
duration of the study (incident TB). Prevalent TB (defined as 
sputum-culture positive) was identified in 87 individuals at the 
time of randomization (when culture results became available), 
who were referred for treatment, rendering them ineligible for 
the RCT. There were 283 controls with IGRA samples availa-
ble and no signs or symptoms of TB during the duration of the 
follow-up (median duration of follow-up in the main study was 
2.5 years), who were randomly chosen just before and just after 
the incident and prevalent cases in the order of recruitment. 
All samples used in the current analyses were collected before 
randomization.
Definition of Tuberculosis Diagnoses
Cases labelled as prior TB had a previous treatment history that 
included diagnosis and treatment for active TB in a healthcare 
facility. There is no routine LTBI diagnosis in South Africa 
using either TST or IGRA, thus all cases labelled as prior TB 
had previously-treated, active TB. Where incident or prevalent 
TB was not microbiologically confirmed, TB was diagnosed 
clinically with a combination of symptoms and a chest X-ray.
Tuberculin Skin Testing and Interferon Gamma Release Assays
The TST (2 TU RT23 purified-protein derivative, Statens 
Serum Institut, Copenhagen, Denmark) was administered on 
the volar aspect of the left forearm by personnel trained in its 
administration. The TST induration was recorded after 48–72 h 
by the ballpoint pen and ruler method. Phlebotomy for IGRA 
(QuantiFERON Gold-in-tube, Qiagen) was performed on the 
same day that the TST was administered and the blood draw 
preceded the placement of the purified-protein derivative. 
The IGRA were performed in a Qiagen-accredited laboratory 
and interpreted according to the manufacturer’s guidelines. 
Laboratory personnel were blinded to TST results and TB 
symptoms, signs, and culture results, while clinicians were 
blinded to IGRA results.
Luminex Multiplex Assay for Cytokines and Chemokines
QFT plasma samples from unstimulated (Nil) and TB-specific, 
antigen-stimulated (Ag) tubes were stored at -80oC until batched 
analyses for the analytes listed in Supplementary Table  1. 
Undiluted (Ag and Nil) QFT plasma samples were assayed 
on 11 plates using customized MilliplexTM kits (Millipore, St 
Charles, MO) on the Bio-Plex platform (Bio-Rad Laboratories, 
Hercules, CA). The upper limit of detection for all analytes was 
10 000 pg/ml, while the mean lower limit of detection from the 
11 plates was as follows (all in pg/ml): epidermal growth factor 
(EGF), 8; IFN-α2, 6; interleukin (IL)-1α, 3; C-X-C motif chemo-
kine 10 (CXCL10), 10; chemokine (C-C motif) ligand (CCL) 3, 
7; CCL4, 3; soluble CD40 ligand (sCD40L), 16; transforming 
growth factor-α (TGF-α), 3; tumor necrosis factor (TNF)-α, 3; 
vascular endothelial growth factor (VEGF), 205; IFN-γ, 3; IL-2, 
3; and IL-10, 3.
Statistical Analysis
Raw out-of-range values were adjusted, by replacing all out-
of-range values lower than the lowest detectable value with 0 
(1027 instances) and replacing all out-of-range values higher 
than the highest detectable value with 10 000 pg/mL (top 
standard, 13 instances) and adding the mean limit of detec-
tion per analyte to all plates. Results are presented for unstim-
ulated (Nil) and stimulated-nil (Ag-Nil) values. Analyte values 
are nearly always presented in a log2-transformed scale as log2 
pg/ml. Subgroups for analysis included the incident TB group, 
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and prevalent TB groups (TB-combined). Frequency (percent) 
or median (inter-quartile range) were calculated by group for 
discrete and continuous values, respectively. Sensitivity analy-
ses were undertaken using the subgroup of culture-confirmed 
incident TB cases, the subgroup randomized to placebo, and 
the subgroup of prevalent TB cases who were smear-negative 
at baseline (smear-negative). The statistical tests used to com-
pare groups were the Fisher’s exact test and Wilcoxon rank 
sum test, as appropriate. Throughout, a nominal threshold for 
statistical significance was set at α  =  .05, and false discovery 
rate correction (FDR) by Benjamini-Hochberg [9] was ap-
plied. These values are reported as P corrected. Data visual-
ization was used to clarify differences between and within 
groups. A  weighted correlation network analysis was carried 
out on the nil and background-corrected analyte levels, strat-
ified by TB status, and presented with correlation diagrams. 
Correlations were estimated using Pearson’s correlation of the 
log2-transformed data.
Supervised learning models were applied to the data to pre-
dict class membership (eg, incident vs prevalent TB) in 2-way 
classifications. In all cases, analyte values were centered and 
scaled prior to input and all models were carried out with 
10-fold cross-validation resampling to estimate classification 
accuracy. Sampling was further stratified by down-sampling 
to ensure balanced class representations in the re-samples. 
Training for the prediction models utilized a grid approach over 
model parameters with a specified grid length. A variable im-
portance score, calculated as a scaled beta coefficient, was used 
as the primary means of determining an individual analyte’s im-
pact on the classification outcome. The classification learners 
assessed included random forests to set a performance ceiling 
[10] and elastic-net regularization (glmnet) [11] for a potentially 
Table 1. Demographic Characteristics at Baseline and Culture Status as Confirmed During Study for Control, Incident TB, Prevalent TB, TB-combined, 
TB-Culture–positive, and Smear-negative Groups 
Variable Level
Control Incident Prevalent Combineda Culture-positiveb Smear-negativec
(n = 283) (n = 51) (n = 87) (n = 138) (n = 106) (n = 79)
BMI, median (IQR) 26 (23, 31) 24 (22, 30) 23 (20, 25) 24 (21, 27) 24 (20, 25) 24 (21, 25)
Age, in years, median (IQR) 34 (30, 39) 33 (30, 38) 35 (30, 39) 34 (30, 39) 34 (30, 38) 35 (30, 39)
Follow-up time, in months,d 
median (IQR)
13 (12, 14) 14 (6, 21) … … … …
Sex Male 67 (24) 12 (24) 27 (31) 39 (28) 32 (30) 22 (28)
Female 216 (76) 39 (76) 60 (69) 99 (72) 74 (70) 57 (72)
Known prior TB No 146 (52) 29 (59) 59 (67) 88 (65) 66 (63) 55 (70)
Yes 136 (48) 20 (41) 28 (32) 48 (35) 39 (37) 24 (30)
TST positive at 5 mm No 160 (60) 25 (57) 30 (40) 55 (46) 36 (40) 26 (37)
Yes 107 (40) 19 (43) 46 (61) 65 (54) 54 (60) 44 (63)
TST positive at 10 mm No 168 (63) 25 (57) 32 (42) 57 (48) 38 (42) 28 (40)
Yes 99 (37) 19 (43) 44 (58) 63 (52) 52 (58) 42 (60)
TB symptoms at baseline No 265 (94) 43 (84) 52 (60) 95 (69) 68 (64) 48 (61)
Yes 18 (6) 8 (16) 35 (40) 43 (31) 38 (36) 31 (39)
CD4 category < 200 112 (40) 25 (49) 59 (69) 84 (61) 68 (65) 53 (68)
200–350 85 (30) 15 (29) 14 (16) 29 (21) 20 (19) 13 (17)
350 + 86 (30) 11 (22) 13 (15) 24 (18) 17 (16) 12 (15)
Ever ART No 93 (36) 21 (44) 55 (65) 76 (57) 61 (59) 23 (79)
Yes 164 (64) 27 (56) 30 (35) 57 (43) 42 (41) 6 (21)
ART <3 months at baseline 
if ART
No 145/164 (88) 27/27 (100) 24/30 (80) 51/57 (90) 36/42 (86) 48 (62)
Yes 19/164 (12) 0 (0) 6/30 (20) 6/57 (10) 6/42 (14) 29 (38)
QFT status at baselinee Negative 155 (55) 27 (53) 30 (34) 57 (41) 38 (36) 26 (33)
Positive 127 (45) 24 (47) 57 (66) 81 (59) 68 (64) 53 (67)
Culture-confirmed TB No 283 (100) 32 (63) 0 (0) 32 (23) 0 (0) 0 (0)
Yes 0 (0) 19 (37) 87 (100) 106 (77) 106 (100) 79 (100)
INH treatment No 148 (53) 33 (65) … … … …
Yes 135 (48) 18 (35) … … … …
Values are given as frequency (%) unless otherwise specified.
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; INH, isoniazid; IQR, interquartile range; QFT, QuantiFERON Gold-in-tube; TB, tuberculosis; TST, Tuberculin skin testing.
aThe combined column includes both the TB incident and TB prevalent groups.
bPrevalent and incident cases with positive culture confirmations.
cThe smear-negative group is the subgroup of TB prevalent cases that were also smear-negative.
dTime from screening date until study drug stop date (controls) or date of TB diagnosis (incident TB).
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interpretable and applicable model. Models were selected on 
the basis of the largest minimum unbiased area under the curve 
(AUC) estimate. Lists of analytes and associated variable im-
portance scores are presented. Receiver-operator curves were 
generated using the predicted vs observed classifications for 
each independent model and were graphed. Additional detailed 
methods are available in the online Supplementary Material.
RESULTS
A total of 421 individuals were included in the analysis, with 
a median of 61 weeks (interquartile range, 28–91) to the onset 
of TB in the incident group. Characteristics did not vary be-
tween the parent screening population and the analysis sample 
(Supplementary Table S2). Between-group characteristics were 
similar for basic demographics and show expected differences 
for TB disease–related measures that were used as part of the 
screening or group definition in the RCT, with higher rates of 
symptoms, QFT, and/or TST positivity in the incident TB and 
prevalent TB groups than in the control group (Table 1). The 
proportion with previously-treated, active TB was higher in the 
control group compared to the TB-combined, incident TB, and 
prevalent TB groups (48% vs 35%, 41% and 32%, respectively; 
overall P = .028), and a higher proportion of the controls had 
previous exposure to ART. The control group also had a lower 
proportion of individuals with cluster of differentiation (CD) 
4 <200 copies/mL compared to the TB-combined group (40% 
vs 61%, respectively; overall P < .001). In the incident TB group, 
37% (19/51) were confirmed as culture positive during fol-
low-up; those not culture-confirmed were diagnosed clinically 
(symptoms and a chest X-ray), due to the diagnosis occurring at 
a site other than the study site.
Analytes From Unstimulated Samples
Analyte concentrations from unstimulated samples were 
higher in the incident and prevalent TB groups compared 
to the control group (Table  2, Figure  1, and Supplementary 
Figure S1). CXCL10, IL-2, and TGF-alpha were highest in the 
prevalent TB group. CCL4, IFN-alpha2, IFN-gamma, IL-10, 
and TNF were highest in the incident TB group; although not 
markedly higher than values seen in the prevalent TB group, 
the trend may indicate underlying inflammatory processes 
leading to TB risk. EGF, IL-1α, and CD40L were highest in 
Table 2. Summary Measures for Each Analyte for the Unstimulated and Background-adjusted Values 
Analyte Control Incident TB Prevalent TB TB-combined
Unstimulated
CCL3 1973.9 (1070.1, 4427.7) 2077.9 (1111.4, 4098.6) 2396.5 (869.0, 4133.5) 2291.0 (969.4, 4117.9)
CCL4 1411.1 (809.9, 2280.0) 1608.4 (959.3, 2774.7) 1394.7 (660.8, 2186.4) 1450.5 (735.9, 2428.5)
CXCL10 4325.9 (2593.1, 8577.5) 5748.5 (2925.8, 8621.0) 6717.0 (3981.0, 10413.3) 6126.6 (3742.1, 9437.5)
EGF 274.0 (178.8, 380.4) 247.7 (148.6, 344.4) 236.6 (169.9, 321.2) 245.9 (164.0, 332.8)
IFN-α2 82.0 (29.0, 127.9) 105.5 (73.3, 145.8) 99.7 (51.3, 149.3) 104.7 (60.7, 148.7)
IFN-γ 8.6 (3.0, 15.2) 11.8 (8.0, 16.4) 11.5 (8.2, 23.0) 11.7 (8.0, 21.0)
IL-10 10.2 (3.0, 23.5) 14.0 (6.9, 27.7) 11.3 (6.1, 21.4) 12.5 (6.2, 25.7)
IL-1α 32.3 (4.8, 83.2) 28.5 (4.5, 59.6) 16.6 (3.6, 48.2) 20.6 (3.6, 56.7)
IL-2 4.0 (3.0, 6.6) 4.7 (3.0, 6.3) 7.7 (6.6, 8.5) 7.1 (5.6, 8.1)
sCD40L 1046.5 (490.5, 2102.6) 889.1 (645.0, 2260.7) 930.5 (415.7, 2915.1) 898.0 (454.6, 2494.2)
TGF-α 12.3 (7.1, 19.4) 14.1 (8.6, 20.6) 16.8 (12.1, 22.7) 16.1 (10.3, 22.1)
TNF 113.8 (47.5, 258.0) 143.1 (58.7, 300.6) 139.4 (67.1, 257.1) 139.4 (61.4, 283.1)
VEGF 379.0 (205.0, 694.0) 205.0 (205.0, 665.8) 456.9 (205.0, 701.5) 369.3 (205.0, 691.4)
Background-adjusted, Stimulated–unstimulated
CCL3 -132.1 (-1197.0, 655.4) 169.7 (-1162.3, 750.3) 44.0 (-851.8, 704.4) 89.2 (-1026.5, 719.1)
CCL4 145.6 (-335.3, 965.1) 404.2 (-212.1, 940.1) 322.4 (-23.1, 1315.7) 351.6 (-76.2, 1124.0)
CXCL10 6144.6 (1698.8, 15576.7) 13 327.6 (4228.4, 34 531.8) 16 242.8 (4853.8, 31 249.0) 14 756.5 (4570.4, 31 947.6)
EGF -37.5 (-76.6, -3.0) -41.0 (-89.5, -5.1) -43.6 (-76.5, -15.3) -42.6 (-82.7, -10.6)
IFN-α2 0.0 (-10.1, 15.6) 9.1 (0.0, 24.3) 6.3 (-2.3, 16.6) 6.5 (0.0, 20.5)
IFN-γ 11.0 (0.0, 74.0) 27.2 (1.6, 89.3) 53.0 (13.4, 192.7) 44.2 (10.6, 177.6)
IL-10 0.0 (-7.5, 1.5) -2.0 (-8.8, 3.0) -2.3 (-8.4, 0.0) -2.2 (-8.5, 0.0)
IL-1α 1.8 (-17.6, 25.5) 0.0 (-18.4, 13.3) 0.0 (-15.3, 16.4) 0.0 (-17.2, 16.0)
IL-2 14.0 (1.3, 86.3) 26.2 (1.8, 140.4) 33.4 (5.8, 152.8) 33.2 (5.4, 143.9)
sCD40L 152.4 (-91.3, 970.7) 291.8 (-55.3, 724.6) 153.4 (-78.2, 1151.1) 170.7 (-65.1, 864.5)
TGF-α 0.0 (-3.6, 2.4) 0.0 (-3.0, 4.0) -0.6 (-4.4, 2.6) 0.0 (-4.1, 3.4)
TNF -7.8 (-74.7, 39.3) 0.7 (-104.2, 35.0) -1.0 (-83.6, 49.9) -0.2 (-92.9, 40.3)
VEGF 0.0 (-227.8, 200.9) 0.0 (-116.7, 298.3) 0.0 (-239.0, 370.7) 0.0 (-197.5, 341.2)
The TB-combined group includes both the TB incident and TB prevalent groups. Values are shown as pg/ml median (IQR). 
Abbreviations: CCL, chemokine (C-C motif) ligand; CXCL10, C-X-C motif chemokine 10; EGF, epidermal growth factor; IFN, interferon; IL, interleukin; IQR, interquartile range; sCD40L, soluble 
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the control group. A  comparison between the control and 
prevalent TB groups showed that the largest group differences 
(>50% median difference, Figure 2) were in analytes CXCL10 
and IL-2 (highest in prevalent), IL-1α (highest in control), and 
VEGF (lowest in incident). A statistical comparison between 
groups indicated CXCL10, IFN-γ, IL-2, and TGF-α remained 
Figure 1. Raw data dot plots for unstimulated (top row) and antigen-stimulated, background-adjusted (bottom row) analytes in control, incident tuberculosis, and prevalent 
tuberculosis comparison groups. Distributions were estimated by violin plots with the median value indicated by a solid vertical line. All values are plotted on a log2 scale, 
and a vertical dashed line is plotted at a difference of 0. Abbreviations: CCL, chemokine (C-C motif) ligand; CXCL10, C-X-C motif chemokine 10; EGF, epidermal growth factor; 
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statistically significant, both after FDR correction (Table 3, P 
corrected < 0.05) when comparing the control and prevalent 
TB groups and with the addition of IFN-α2 when comparing 
the control and TB-combined groups. No analytes remained 
statistically significant when comparing the control and inci-
dent TB groups after FDR correction, and only IL-2 remained 
significant when comparing the prevalent TB with incident 
TB groups (Table 3).
Analytes From Stimulated Samples Corrected for Background 
A number of analytes had higher unstimulated concentra-
tions, so background correction could result in negative 
median (Ag-nil) differences (most notably TNF, IL-1α, 
IL-10, EGF, and CCL3; Table 2, Table 3, and Supplementary 
Figure  S2). In the control vs prevalent TB and control vs 
TB-combined group comparisons, CXCL10, IFN-γ, and 
IL-2 remained statistically significant after FDR correction. 
CXCL10 also remained significantly different in the con-
trol vs incident TB group comparison; however, no analyte 
remained significant for (Ag-Nil) after FDR correction in the 
prevalent vs incident TB group comparison.
Weighted Correlation Network Analysis
A weighted correlation network analysis on the nil analyte 
concentrations (Figure 3) demonstrated a cluster of positive-
ly-correlated analytes, including IL-2, IFN-γ, and INF-α2 in 
the control group and, to a lesser extent, in the prevalent TB 
group, which is absent in the incident TB group. The second 
cluster identified included CCL3, CCL4, IL-1α, IL-10, and 
TNF, with varying strengths. While this cluster was pres-
ent in all 3 groups, it is notable that the correlation between 
CCL3 and CCL4 was positive only in the incident TB group 
(Figure 3). The same analysis on the background-corrected 
analyte values led to a similar identification of an IL-2 and 
IFN-γ correlation, but this time in association with CXCL10 
instead of IFN-α2 (Supplementary Figure  S3). This cluster 
was present in all 3 groups. There was a strong correlation, 
in the incident TB group only, between INF-γ and INF-α2, 
which was small and negative in both the control and prev-
alent TB groups. There were notable negative correlations in 
the TB incident group, specifically between IL-10 and INF-γ, 
while a strong positive correlation was seen between IFN-γ 
and IFN- α2, but was present in this group only.
Predictive Models
Results of predictive model fitting showed the tree-based 
ensemble models of random forests to be most accurate, 
although more interpretable models (glmnet) also per-
formed reasonably well by comparison with AUC (Figure 4, 
Supplementary Table  S5, and Supplementary Figure  S4). 
Models using the unstimulated analyte values as input were 
better able to discriminate between the control and prevalent 
TB groups (random forest AUC  =  0.9, glmnet AUC  =  0.7) 
than models using the background-corrected (Ag-Nil) 
values. The discrimination between the incident TB and 
prevalent TB groups was also reasonable (AUC > 0.8); how-
ever, the models poorly discriminated between the control 
and incident TB groups. Model-predicted variable impor-
tance scores ranked IL-2 and IFN-γ at or near the top for all 
comparisons, except the comparison between the control vs 
incident TB group (Table 4). Models using the Ag-Nil values 
Figure  2. Standardized differences in unstimulated group medians (log2 pg/
mL) between the incident tuberculosis group (grey) or prevalent tuberculosis group 
(black) vs the control group for each analyte. Negative differences mean the inci-
dent tuberculosis or prevalent tuberculosis group medians were lower than the 
control group medians. Abbreviations: CCL, chemokine (C-C motif) ligand; CXCL10, 
C-X-C motif chemokine 10; EGF, epidermal growth factor; IFN, interferon; IL, inter-
leukin; sCD40L, soluble CD40 ligand; TGF-α, transforming growth factor-α; TNF, 
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as the input performed poorly by comparison, requiring a 
large number of analytes to reach an overall lower AUC (max 
AUC < 0.7 for all models; Table 4).
Sensitivity Analyses
There were 4 additional sensitivity analyses. First, we utilized 
the culture-confirmed TB samples (n = 106 from the 87 preva-
lent and 19 incident TB patients) in place of the TB-combined 
group as a comparison group (Table 1). After FDR adjustment, 
CXCL10, IFN-γ, IL-2, and TGF-α remained statistically signif-
icant in the control vs culture-confirmed comparison of the 
unstimulated values, while only CXCL10, IFN-γ, and IL-2 did so 
using the Ag-Nil values (Table 3). Second, we utilized the subset 
(n = 181) of individuals randomized to placebo (ie, those that 
did not receive IPT treatment) to investigate the development 
of incident TB (Supplementary Table S3). Baseline characteris-
tics in this subgroup were comparable. Out of 334 randomized 
individuals, 181 (54%) were randomized to placebo; 33 of the 
181 (18%) placebo recipients developed incident TB, compared 
to 18 of the 153 (12%) participants who were randomized to IPT 
treatment (95% confidence interval for difference, -0.01–0.12; 
P = .1016). No analytes remained significant after FDR correc-
tion. Third, the subset of sputum smear–negative TB-prevalent 
patients (n = 79, Tables 1 and 3) were compared to the controls. 
After FDR correction, IFN-γ, IL-2, and TGF-α remained sta-
tistically significant using the nil analyte values, and CXCL10 
and IFN-γ remained significant when using the Ag-nil values. 
Fourth, based on TB diagnosis time in the incident TB group, 
split by median time to TB (<=61 weeks, >62 weeks; analyte 
values are summarized in Supplementary Table S4).
DISCUSSION
We evaluated the predictive value of selected analytes as poten-
tial biomarkers for HIV-associated TB. This is the first study of 
Table 3. P Values for Group Comparisons Using the Unstimulated Values and the Background-adjusted Values 
Control vs Combined
Control vs 
Culture-positive Control vs Incident Control vs Prevalent
Control vs 


























CCL3 .7950 .9154 .9996 .9996 .9385 .9996 .7701 .9154 .8610 .9733 .8947 .9970
CCL4 .7551 .9154 .5566 .7616 .3007 .5097 .2410 .4272 .3624 .5543 .1055 .2351
CXCL10 .0082 .0375 .0051 .0251 .4181 .5947 .0030 .0170 .0138 .0569 .1701 .3266
EGF .0872 .2000 .1597 .3193 .1416 .2907 .2196 .3984 .1752 .3266 .6930 .8718
IFN-α2 .0047 .0246 .0360 .1124 .0148 .0576 .0434 .1249 .0662 .1564 .5752 .7736
IFN-γ <.0001 .0002 <.0001 .0004 .0138 .0569 .0001 .0005 .0005 .0031 .4194 .5947
IL-10 .0299 .0973 .0654 .1564 .0511 .1375 .1327 .2875 .1375 .2899 .3347 .5221
IL-1α .0257 .0870 .0255 .0870 .3773 .5582 .0186 .0690 .0446 .1249 .2997 .5097
IL-2 <.0001 <.0001 <.0001 <.0001 .9980 .9996 <.0001 <.0001 <.0001 <.0001 <.0001 <.0001
sCD40L .9480 .9996 .9733 .9996 .9091 .9987 .9968 .9996 .7203 .8918 .7947 .9154
TGF-α .0004 .0027 .0001 .0008 .3256 .5183 .0001 .0004 .0004 .0027 .0575 .1496
TNF .3179 .5166 .1759 .3266 .6603 .8584 .3071 .5097 .3793 .5582 .7981 .9154
VEGF .4774 .6649 .6546 .8584 .0606 .1525 .6888 .8718 .9970 .9996 .0448 .1249
Background-adjusted, Stimulated-unstimulated
CCL3 .3146 .5707 .6599 .7993 .5153 .7303 .3806 .6316 .6651 .7993 .9683 .9802
CCL4 .0540 .2004 .0486 .1994 .4163 .6494 .0459 .1994 .0479 .1994 .6528 .7993
CXCL10 <.0001 <.0001 <.0001 <.0001 .0024 .0145 <.0001 <.0001 <.0001 <.0001 .4480 .6721
EGF .1745 .4002 .1485 .3862 .4281 .6548 .2124 .4555 .1538 .3869 .8496 .9202
IFN-α2 .0101 .0564 .0516 .2004 .0129 .0672 .1000 .2890 .1349 .3629 .2451 .4878
IFN-γ <.0001 .0004 <.0001 <.0001 .1873 .4175 <.0001 .0001 <.0001 <.0001 .0722 .2347
IL-10 .1731 .4002 .2318 .4758 .7167 .8344 .1171 .3262 .0691 .2345 .4862 .7023
IL-1α .2502 .4878 .3897 .6332 .4145 .6494 .3421 .5929 .1743 .4002 .9067 .9430
IL-2 .0020 .0132 .0011 .0083 .2161 .4555 .0012 .0083 0.0004 .0038 .2606 .4958
sCD40L .4807 .7023 .9802 .9802 .6365 .7993 .5466 .7336 .8192 .9202 .9437 .9686
TGF-α .8734 .9206 .8524 .9202 .3745 .6316 .6661 .7993 .6297 .7993 .3338 .5918
TNF .7048 .8329 .5549 .7336 .8612 .9202 .5243 .7303 .8372 .9202 .5340 .7307
VEGF .0668 .2345 .0176 .0859 .2712 .5036 .0970 .2890 .0907 .2831 .7961 .9132
P values remaining significant after false-discovery rate adjustment are in bold.
Abbreviations: CCL, chemokine (C-C motif) ligand; CXCL10, C-X-C motif chemokine 10; EGF, epidermal growth factor; IFN, interferon; IL, interleukin; sCD40L, soluble CD40 ligand; TGF-α, 






/cid/article-abstract/69/2/295/5106993 by guest on 25 Septem
ber 2019
302 • CID 2019:69 (15 July) • Lesosky et al
this size, nested within a 4-year prospective cohort, using sam-
ples collected at the screening stage of a large RCT, that showed 
that adding IPT to ART reduced the TB incidence in patients 
with HIV-1 infections [8]. A unique feature of our study is the 
comparison of 13 biomarkers in the plasma from prevalent and 
incident TB patients. Novel TB biomarkers, other than IFN-γ, 
might significantly contribute to the prediction of prevalent TB 
and improve the multivariate risk prediction for incident TB.
Zak et al [12] and Suliman et al [13] successfully identified 
6 and 4 gene RNA signatures, respectively, in peripheral blood 
that can partially predict a progression to TB. While these find-
ings are important, a more applicable predictive tool would be 
a test based on measuring soluble markers in easily-accessible 
samples suited for use in primary or secondary healthcare facil-
ities by health care personnel with minimal training.
Recent work has demonstrated that Quantiferon supernatants 
can be useful in identifying combination biomarkers to diagnose 
pulmonary TB [14, 15]. Our findings are in keeping with those 
described by Chegou et  al, although with some differences, as 
their patient population was HIV-uninfected [16]. Significantly 
different analyte concentrations between groups in the unstim-
ulated samples were seen in CXCL10, IFN-γ, IL-2, and TGF-α, 
when comparing the control with prevalent TB groups, and also 
with IFN-α2 when comparing the control with TB-combined 
groups. The role of CXCL10, with or without IFN-γ, in both adult 
and paediatric populations, has been highlighted previously [17, 
18]. In our analysis, CXCL10 remained statistically significant 
between both the control and prevalent groups, as well as the 
incident TB group, after correction for multiple comparisons in 
background-corrected, antigen-stimulated samples. The finding 
that unstimulated IL-2 concentrations differentiated prevalent 
from incident TB samples after correction for statistical compar-
isons suggests that IL-2 may be an important marker of TB pro-
gression and warrants further investigation, although the median 
concentrations are low. Our predictive model analysis also ranked 
unstimulated IL-2 (together with IFN-γ) highly for all compar-
isons, except for control versus incident TB. There is a dynamic 
relationship between IFN-γ– and IL-2–secreting antigen-specific 
T cells in patients during and after treatment for TB, reflecting 
that it is likely driven by antigen load [19]. These findings illustrate 
that the ability of unstimulated plasma analyte concentrations to 
better identify TB risks in these HIV-1–infected patients demon-
strates underlying inflammatory processes, and higher overall 
background activation might render them more susceptible to 
progression to TB.
While our study has strengths, in particular of power, it also 
has limitations, including the limited number of preselected 
analytes measured, the lack of an external validation cohort, 
and the sampling, which relied on sample availability, leading 
to possible bias (ie, the lack of QFT-indeterminate individuals 
in the analysis set). The randomization to IPT or placebo also 
affected the outcome of our investigation, since IPT reduced in-
cident TB, also reducing the ability of biomarkers to predict it 
in this cohort. Additionally, ongoing TB exposure post-enroll-
ment could have contributed to the inability of these markers to 
predict incident TB, potentially measuring the baseline plasma 
Control (Nil) Incident (Nil) Prevalent (Nil)
Figure 3. Weighted correlation networks in (left to right) controls, incident, and prevalent tuberculosis groups. Solid lines are indicative of positive correlations, dashed 
lines indicate negative correlations, and the strength of a correlation is indicated by the thickness of the line. Abbreviations: CCL, chemokine (C-C motif) ligand; CXCL10, C-X-C 
motif chemokine 10; EGF, epidermal growth factor; IFN, interferon; IL, interleukin; sCD40L, soluble CD40 ligand; TGF-α, transforming growth factor-α; TNF, tumor necrosis 
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biomarkers that were present prior to the TB exposure and that 
may have led to active disease. Additional weaknesses include 
poor predictive performance in the analysis and unbalanced 
classes, since down-sampling reduces the effective sample size. 
Classification performance may also be impacted by unmeas-
ured confounding and effect modification, potentially related 
to the unique setting in South Africa. However, with these 
limitations in mind, our data, indicating that a combination 
of plasma biomarkers may be used to detect prevalent TB in 
HIV-1–infected individuals, is potentially an important finding. 
It is also interesting that unstimulated analytes performed best, 
therefore potentially avoiding the need to culture cells or whole 
blood in vitro. Our findings could pave the way towards further, 
larger, prospective studies that would evaluate soluble plasma 
biomarkers that might effectively predict incident TB in HIV-
infected patients.
Figure 4. Receiver operator curves (ROCs) for primary comparison using nil data. Each curve represents an independent, cross-validated, predictive model with different 
tuning parameters. The left panels are curves estimated using glmnet-penalized regression and the right panel ROC curves were estimated using random forests: each row 
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Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility of 
the authors, so questions or comments should be addressed to the corre-
sponding author.
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